Indian astronaut Shubhanshu Shukla is currently on the International Space Station as part of Axiom Mission 4, conducting ...

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

Houston’s Axiom Space launched its fourth human spaceflight mission on Wednesday. One of the mission’s experiments hopes to ...

Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress underway in London.

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Discover how the Axiom-4 mission to the ISS is revolutionizing diabetes treatment with groundbreaking research on glucose ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Axiom-4 astronauts are set to study insulin behaviour in microgravity, potentially transforming diabetes treatment and aiding ...

During their 14-day stay aboard the orbital lab, some astronauts on the Axiom-4 mission will be wearing continuous glucose ...

AAs India’s astronaut Shubhanshu Shukla has blasted off into space on the Axiom-4 mission, he will be part of several medical ...

While many systems already pair continuous glucose monitors (CGMs) and insulin pumps, PharmaSens and SiBionics may have ...